KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Cash from Financing Activities (2023 - 2025)

Biocryst Pharmaceuticals' Cash from Financing Activities history spans 9 years, with the latest figure at -$218.0 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 5320.54% year-over-year to -$218.0 million; the TTM value through Dec 2025 reached -$349.9 million, down 5974.14%, while the annual FY2025 figure was -$349.9 million, 5974.14% down from the prior year.
  • Cash from Financing Activities reached -$218.0 million in Q4 2025 per BCRX's latest filing, down from -$58.8 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $29.4 million in Q2 2023 to a low of -$218.0 million in Q4 2025.
  • Average Cash from Financing Activities over 3 years is -$26.9 million, with a median of -$1.5 million recorded in 2024.
  • The largest YoY upside for Cash from Financing Activities was 150.48% in 2025 against a maximum downside of 5320.54% in 2025.
  • A 3-year view of Cash from Financing Activities shows it stood at -$3.2 million in 2023, then decreased by 26.73% to -$4.0 million in 2024, then plummeted by 5320.54% to -$218.0 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Cash from Financing Activities are -$218.0 million (Q4 2025), -$58.8 million (Q3 2025), and -$73.7 million (Q2 2025).